GlassScriptPhysician profile
Sergio J Jacinto
NPI 1558394114
$21,026.93
in general payments reported to CMS, 2019-2025
46 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,120 · 2020: $1,943 · 2021: $2,650 · 2022: $2,264 · 2023: $4,358 · 2024: $3,171 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,766 · Travel and Lodging: $1,283 · Education: $0.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,766.07 |
| Travel and Lodging | $1,283.16 |
| Education | $0.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $3,873.20 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $2,512.02 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Ironshore Pharmaceuticals INC. | $1,697.93 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $1,341.75 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $1,338.08 | 2019-2025 | Qelbree, Qelbree |
| Eisai INC. | $1,281.68 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $1,185.89 | 2022-2025 | |
| Tris Pharma INC | $884.54 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Corium, LLC | $835.18 | 2021-2025 | Azstarys |
| Catalyst Pharmaceuticals, INC. | $820.36 | 2023-2025 | Fycompa |
| Neurelis, INC. | $706.47 | 2020-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $538.49 | 2023-2024 | Aptiom |
| Sk Life Science, INC. | $442.81 | 2020-2025 | Xcopri |
| Collegium Pharmaceutical, INC. | $415.59 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $370.12 | 2024-2025 | Daybue |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Jacinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.